Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2225143 | 0.80 | — | — | |
| SCHEMBL17902633 | 0.80 | NOTUM (0.40) | LMNATP53MDM2 | |
| SCHEMBL17898504 | 0.77 | TP53 (0.35) | LMNATP53MDM2 | |
| SCHEMBL15782152 | 0.75 | LMNA (0.46) | LMNATP53MDM2 | |
| SCHEMBL17898510 | 0.75 | CYP2D6 (0.34) | LMNATP53MDM2 | |
| SCHEMBL15782150 | 0.75 | POLB (0.40) | LMNATP53MDM2 | |
| SCHEMBL29573549 | 0.74 | — | — | |
| SCHEMBL59155 | 0.71 | — | — | |
| SCHEMBL10871994 | 0.70 | LMNA (0.59) | LMNA | |
| SCHEMBL2297517 | 0.70 | LMNA (0.59) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3237903-B1 | METHODS FOR AUTHENTICATION AND IDENTIFICATION OF PETROLEUM PRODUCTS | EXXONMOBIL RES & ENG CO (US) | 2020-02-26 | — | — | EP | claimed |
| EP-3212645-B1 | PROCESS FOR MAKING TRICYCLIC LACTAM COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2018-11-28 | — | — | EP | claimed |
| EP-4370521-A1 | NOVEL COMPOUNDS FOR THE DIAGNOSIS OF TDP-43 PROTEINOPATHIES | AC Immune SA (CH) | 2024-05-22 | — | — | EP | disclosed |
| WO-2024068948-A1 | NOVEL COMPOUNDS FOR THE DIAGNOSIS OF TDP-43 PROTEINOPATHIES | AC IMMUNE SA (CH) | 2024-04-04 | — | — | WO | disclosed |
| CN-116981667-A | Heterocyclic inhibitors of EGFR and/or HER2 for cancer treatment | 蝎子疗法股份有限公司 | 2023-10-31 | — | — | CN | disclosed |
| WO-2023205595-A2 | EGFR INHIBITORS IN CANCER TREATMENT | CELYN THERAPEUTICS, INC (US) | 2023-10-26 | — | — | WO | disclosed |
| EP-3604308-B1 | SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | BOEHRINGER INGELHEIM INT (DE) | 2023-09-13 | — | — | EP | disclosed |
| WO-2023285661-A1 | NOVEL COMPOUNDS FOR THE DIAGNOSIS OF TDP-43 PROTEINOPATHIES | AC IMMUNE SA (CH) | 2023-01-19 | — | — | WO | disclosed |
| US-20220153733-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2022-05-19 | — | — | US | disclosed |
| EP-3959211-A1 | 4H-PYRROLO[3,2-C]PYRIDIN-4-ONE COMPOUNDS | Bayer Aktiengesellschaft (DE) | 2022-03-02 | — | — | EP | disclosed |
| EP-3297438-B1 | CCR2 MODULATORS | CHEMOCENTRYX INC (US) | 2021-10-20 | — | — | EP | disclosed |
| US-20130296317-A1 | LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | MERCK SHARP & DOHME LLC | 2013-11-07 | — | — | US | disclosed |
| US-20130259830-A1 | CRTH2 MODULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2013-10-03 | — | — | US | disclosed |
| WO-2013130660-A1 | AMIDES AS PIM INHIBITORS | AMGEN INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| EP-2632260-A1 | LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | Merck Sharp & Dohme Corp. (US) | 2013-09-04 | — | — | EP | disclosed |
| EP-2526945-A1 | New CRTH2 Antagonists | Almirall, S.A. (ES) | 2012-11-28 | — | — | EP | disclosed |
| WO-2012058193-A1 | LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2012-05-03 | — | — | WO | disclosed |
| WO-2012009134-A1 | CRTH2 MODULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | WO | disclosed |
| EP-2380890-A1 | New 7,8-dihydro-1,6-naphthyridin-5(6h)-one-derivatives as PDE4 inhibitors | Almirall, S.A. (ES) | 2011-10-26 | — | — | EP | disclosed |
| US-20110253549-A1 | WASHING APPARATUS AND METHOD OF DEODORIZING WASHING WATER | KANNO MINORU | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296317-A1 | LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | LRRK2, PARK7, AKT1 | LMNA 2399/4885TP53 1954/4885MDM2 355/4885 |
| US-20220153733-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CCR2, CCR1, CCR5 | LMNA 4761/4885TP53 3747/4885MDM2 3064/4885 |
| US-20130259830-A1 | CRTH2 MODULATORS | HRH2, HRH1, NR1H2 | LMNA 4624/4885TP53 4766/4885MDM2 4235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.